

Date: October 2, 2025

To: Iowa Vaccines for Children (VFC) Program Providers

From: Iowa VFC Program

Re: Vaccine Update – Penmency MenABCWY Vaccine

Effective October 2, 2025, the Iowa VFC Program will allow providers to order Penmenvy, a MenABCWY vaccine, manufactured by GlaxoSmithKline (GSK).

MenABCWY is approved as an option when both MenACWY and Men B vaccines are indicated at the same visit. Penmenvy is indicated for healthy individuals aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccination, and individuals aged 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines.

A detailed MenABCWY vaccine summary is available [here](#) and includes information on administration, dosage, schedule, and contraindications.

VFC Program Ordering

When placing an order for MenABCWY vaccine, VFC Program providers should review the clinic's vaccine inventory to identify all other vaccines needed. VFC Program providers should continue to place vaccine orders consistent with their economic order quantity (monthly, bimonthly or quarterly). Vaccine wastage and unnecessary vaccine expiration may result in restitution per the [Vaccine Restitution Policy](#).

For questions, contact the Iowa VFC Program at iowaVFC@hhs.iowa.gov.